Should liver transplantation in patients with model for end-stage liver disease scores ≤ 14 be avoided? A decision analysis approach

Liver Transplantation

Volumn 15, Issue 2, 2009, Pages 242-254

  Perkins, James D ^a   Halldorson, Jeffrey B ^a   Bakthavatsalam, Ramasamy ^a   Fix, Oren K ^a   Carithers Jr , Robert L ^a   Reyes, Jorge D ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DECISION ANALYSIS APPROACH; GRAFT SURVIVAL; HEALTH CARE POLICY; HUMAN; INSTRUMENT VALIDATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MODEL FOR END STAGE LIVER DISEASE SCORE; ORGAN DONOR; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SENSITIVITY ANALYSIS; SIMULATION; STATISTICAL MODEL; SURGICAL MORTALITY;

ADULT; FEMALE; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MODELS, THEORETICAL; NEEDS ASSESSMENT; SEVERITY OF ILLNESS INDEX; WAITING LISTS;

EID: 67649209473     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21703     Document Type: Article

References (45)

1. Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 2003;9:12-18.
2. Freeman RB, Harper A, Edwards EB. Excellent liver transplant survival rates under the MELD/PELD system. Transplant Proc 2005;37:585-588.
3. Freeman RB Jr, Wiesner RH, Roberts JP, McDiarmid S, Dykstra DM, Merion RM. Improving liver allocation: MELD and PELD. Am J Transplant 2004;4:114-131.
4. Freeman RB. MELD: the holy grail of organ allocation? Reply. J Hepatol 2005;42:478-479.
5. Ahmad J, Downey KK, Akoad M, Cacciarelli TV. Impact of the MELD score on waiting time and disease severity in liver transplantation in United States veterans. Liver Transpl 2007;13:1564-1569.
6. Kamath PS, Kim WR, and Advanced Liver Disease Study Group. The Model for End-Stage Liver Disease (MELD). Hepatology 2007;45:797-805.
7. Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008;8: 958-976.
8. Fabregas L, Conte A. Transplanting livers too soon. Pittsburgh Tribune-Review. March 9, 10, 11, and 13, 2008. Available at: www.pittsburghlive.com/x/pittsburghtrib/news/s_556307.html. Accessed November 2008.
9. Olthoff KM, Brown RS Jr, Delmonico FL, Freeman RB, Mc-Diarmid SV, Merion RM, et al. Summary report of a national conference: evolving concepts in liver allocation in the MELD and PELD era. Liver Transpl 2004:10:A6-A22.
10. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005;5:307-313.
11. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008;8:419-425.
12. Wiesner R, Lake JR, Freeman RB, Gish RG. Model for End-Stage Liver Disease (MELD) exception guidelines. Liver Transpl 2006;12:S85-S87.
13. Decision analysis primer. In: TreeAge Pro. Your Complete Guide to TreeAge Pro: the Essential Tool for Today's Decision Maker. Williamstown, MA: TreeAge Software;2007:7-14.
14. Lee JM, Kopans DB, McMahon PM, Halpern EF, Ryan PD, Weinstein MC, et al. Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging - Markov Monte Carlo decision analysis. Radiology 2008;246:763-771.
15. Ramsey SD, McIntosh M, Etzioni R, Urban N. Simulation modeling of outcomes and cost effectiveness. Hematol Oncol Clin North Am 2000;14:925-938.
16. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-831.
17. Pasta DJ, Taylor JL, Henning JM. Probabilistic sensitivity analysis incorporating the bootstrap: an example comparing treatments for the eradication of Helicobacter pylori. Med Decis Making 1999;19:353-363.
18. Efron B. The Jackknife, the Bootstrap, and Other Resampling Plans; Philadelphia, PA: Society for Industrial and Applied Mathematics; 1982.
19. Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science 1974;185:1124-1131.
20. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-1730.
21. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33: 464-470.
22. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001;7:567-580.
23. United Network for Organ Sharing. Allocation of livers. Available at: http://www.unos.org/policiesandbylaws2/policies/pdfs/policy_8.pdf. Accessed November 2008.
24. Ahmad J, Bryce CL, Cacciarelli T, Roberts MS. Differences in access to liver transplantation: disease severity, waiting time, and transplantation center volume. Ann Intern Med 2007;146:707-713.
25. Amin MG, Wolf MP, TenBrook JA Jr, Freeman RB Jr, Cheng SJ, Pratt DS, et al. Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: a decision analysis. Liver Transpl 2004;10:1468-1475.
26. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783-790.
27. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular cafrcinoma; impact of the MELD allocation system and predictors of survival. Gastroenterology 2008;134:1342-1351.
28. Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008;8:839-846.
29. Habib S, Berk B, Chang CC, Demetris AJ, Fontes P, Dvorchik I, et al. MELD and prediction of post-liver transplantation survival. Liver Transpl 2006;12:440-447.
30. Onaca NN, Levy, MF, Sanchez EQ, Chinnakotla S, Fasola CG, Thomas MJ, et al. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. Liver Transpl 2003;9:117-123.
31. Saab S, Wang V, Ibrahim AB, Durazo F, Han S, Farmer DG, et al. MELD score predicts 1-year patient survival post-orthotopic liver transplantation. Liver Transpl 2003; 9:473-476.
32. Hayashi PH, Forman L, Steinberg T, Bak T, Wachs M, Kugelmas M, et al. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients. Liver Transpl 2003;9:737-740.
33. Desal NM, Mange KC, Crawford MD, Abt PL, Frank AM, Markmann JW, et al. Predicting outcome after liver transplantation: utility of the Model for End-Stage Liver Disease and a newly derived discrimination function. Transplantation 2004;77:99-106.
34. Akyildiz M, Karasu Z, Arikan C, Kilic M, Zeytunlu M, Gunsar F, et al. Impact of pretransplant MELD score on posttransplant outcome in living donor liver transplantation. Transplant Proc 2004;36:1442-1444.
35. Onaca NN, Levy MF, Netto GJ, Thomas MJ, Sanchez EQ, Chinnakotla S, et al. Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. Am J Transplant 2003;3:626-630.
36. Jacob M, Copley LP, Lewsey JD, Gimson A, Toogood GJ, Rela M, et al. Pretransplant MELD score and post liver transplantation survival in the UK and Ireland. Liver Transpl 2004;10:903-907.
37. Gambato M, Senzolo M, Canova D, Germani G, Tomat S, Masier A, et al. Algorithm for prioritization of patients on the waiting list for liver transplantation. Transplant Proc 2007;39:1855-1856.
38. Austin MT, Poulose BK, Ray WA, Arbogast PG, Feurer ID, Pinson CW. Model for End-Stage Liver Disease: did the new liver allocation policy affect waiting list mortality? Arch Surg 2007;142:1079-1085.
39. Silberhumer GR, Hetz H, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Soliman T, Steininger R, et al. Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival? Transpl Int 2006;19:275-281.
40. Adler M, De Gendt E, Vereerstraeten P, Degré D, Bourgeois N, Boon N, et al. Value of the MELD score for the assessment of pre- and post-liver transplantation survival. Transplant Proc 2005;37:2863-2864.
41. Yoo HY, Thuluvath PJ. Short-term post liver transplant survival after the introduction of MELD scores for organ allocation in the United States. Liver Int 2005;25:536-541.
42. Huo TL, Lin HC, Wu JC, Lee FY, Hou MC, Lee PC, et al. Different Model for End-Stage Liver Disease score block distributions may have a variable ability for outcome prediction. Transplantation 2005;80:1414-1418.
43. Axelrod DA, Koffron AJ, Baker T, Al-Saden P, Dixler I, McNatt G, et al. The economic impact of MELD on liver transplant centers. Am J Transplant 2005;5:2297-2301.
44. Washburn WK, Pollock BH, Nichols L, Speeg KV, Halff G. Impact of recipient MELD score on resource utilization. Am J Transplant 2006;6:2449-2454.
45. Ammori JB, Pelletier SJ, Lynch R, Cohn J, Ads Y, Campbell DA, et al. Incremental costs of post-liver transplantation complications. J Am Coll Surg 2008;206:89-95.